@kirolloskamel.bsky.social
Kiwi classical Haematologist working in Townsville - passionate about lab haem, Haemostasis and thrombosis. Coptic Orthodox Christian.
🚨FDA approves rilzabrutinib – 1st BTK inhibitor for ITP
LUNA3: heavily pre-treated pts (median 4 prior lines, 28% splenectomy), durable PLT response 23% vs 0% PBO; 64% initial rise; median 15d. ↓ rescue Rx, ↓ bleeding, ↑ QoL. Well-tolerated
Australia needs this! 🇦🇺
@thanzblood.bsky.social #hemesky
LUNA3: heavily pre-treated pts (median 4 prior lines, 28% splenectomy), durable PLT response 23% vs 0% PBO; 64% initial rise; median 15d. ↓ rescue Rx, ↓ bleeding, ↑ QoL. Well-tolerated
Australia needs this! 🇦🇺
@thanzblood.bsky.social #hemesky
September 1, 2025 at 7:15 PM
🚨FDA approves rilzabrutinib – 1st BTK inhibitor for ITP
LUNA3: heavily pre-treated pts (median 4 prior lines, 28% splenectomy), durable PLT response 23% vs 0% PBO; 64% initial rise; median 15d. ↓ rescue Rx, ↓ bleeding, ↑ QoL. Well-tolerated
Australia needs this! 🇦🇺
@thanzblood.bsky.social #hemesky
LUNA3: heavily pre-treated pts (median 4 prior lines, 28% splenectomy), durable PLT response 23% vs 0% PBO; 64% initial rise; median 15d. ↓ rescue Rx, ↓ bleeding, ↑ QoL. Well-tolerated
Australia needs this! 🇦🇺
@thanzblood.bsky.social #hemesky
Results of HIPRO single centre RCT out In pts w/ provoked VTE + enduring risk (obesity, chronic inflammation, CVD, lung dz), 12 mo low-dose apixaban cut recurrence 1.3% vs 10% (HR 0.13, NNT≈12). Major bleed rare; CRNM bleed ↑ (NNH≈32). Subgroup analysis underpowered.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | NEJM
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk f...
www.nejm.org
September 1, 2025 at 7:05 PM
Results of HIPRO single centre RCT out In pts w/ provoked VTE + enduring risk (obesity, chronic inflammation, CVD, lung dz), 12 mo low-dose apixaban cut recurrence 1.3% vs 10% (HR 0.13, NNT≈12). Major bleed rare; CRNM bleed ↑ (NNH≈32). Subgroup analysis underpowered.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Poll question for haematologists
Is there still a role for Activated Protein C Resistance testing in the assessment for thrombophilia, when FVL PCR is readily available?
1️⃣ YES
2️⃣ NO
Reply with number below.
#hemesky
Is there still a role for Activated Protein C Resistance testing in the assessment for thrombophilia, when FVL PCR is readily available?
1️⃣ YES
2️⃣ NO
Reply with number below.
#hemesky
August 1, 2025 at 10:14 PM
Poll question for haematologists
Is there still a role for Activated Protein C Resistance testing in the assessment for thrombophilia, when FVL PCR is readily available?
1️⃣ YES
2️⃣ NO
Reply with number below.
#hemesky
Is there still a role for Activated Protein C Resistance testing in the assessment for thrombophilia, when FVL PCR is readily available?
1️⃣ YES
2️⃣ NO
Reply with number below.
#hemesky
www.sciencedirect.com/science/arti...
I came across this “practical guideline” for major heritable thrombophilia. I am not sure I agree with some of their recommendations - should generate an interesting debate though. Also have never tested for the F2 AT resistance mutations!
#hemesky
I came across this “practical guideline” for major heritable thrombophilia. I am not sure I agree with some of their recommendations - should generate an interesting debate though. Also have never tested for the F2 AT resistance mutations!
#hemesky
Practical guideline for major hereditary thrombophilia
www.sciencedirect.com
July 6, 2025 at 7:23 AM
www.sciencedirect.com/science/arti...
I came across this “practical guideline” for major heritable thrombophilia. I am not sure I agree with some of their recommendations - should generate an interesting debate though. Also have never tested for the F2 AT resistance mutations!
#hemesky
I came across this “practical guideline” for major heritable thrombophilia. I am not sure I agree with some of their recommendations - should generate an interesting debate though. Also have never tested for the F2 AT resistance mutations!
#hemesky
Combined HbC trait and G6PD deficiency!
A previously healthy 7-year-old African American boy was admitted for anemia and hemoglobinuria. buff.ly/WDXkNJT #hemesky #BloodWork
June 26, 2025 at 1:52 AM
Combined HbC trait and G6PD deficiency!
Fascinating paper; which reinforces my own clinical experience that the majority of clinically encountered type I protein S deficiency behave like a low risk thrombophilia, presumably as they have the missense variant. We need more studies like this!
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Population-Scale Studies of Protein S Abnormalities and Thrombosis
This cross-sectional study evaluates the risk associated with protein S deficiency across multiple arterial thrombosis phenotypes in population-level cohorts.
jamanetwork.com
May 4, 2025 at 6:42 AM
Fascinating paper; which reinforces my own clinical experience that the majority of clinically encountered type I protein S deficiency behave like a low risk thrombophilia, presumably as they have the missense variant. We need more studies like this!
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
April 11, 2025 at 9:50 PM
Reposted
📢 Hematology Breakthrough! 🧑⚕️🔬
📌 Follow us for more updates: @displaycia.bsky.social
🔗 Read more: displaycia.com/medic...
#Hematology #HealthScience #Breakthrough #MedicalScience #ManuscriptSubmission #ScientificResearch #Innovation #Displaycia
📌 Follow us for more updates: @displaycia.bsky.social
🔗 Read more: displaycia.com/medic...
#Hematology #HealthScience #Breakthrough #MedicalScience #ManuscriptSubmission #ScientificResearch #Innovation #Displaycia
April 10, 2025 at 11:45 AM
📢 Hematology Breakthrough! 🧑⚕️🔬
📌 Follow us for more updates: @displaycia.bsky.social
🔗 Read more: displaycia.com/medic...
#Hematology #HealthScience #Breakthrough #MedicalScience #ManuscriptSubmission #ScientificResearch #Innovation #Displaycia
📌 Follow us for more updates: @displaycia.bsky.social
🔗 Read more: displaycia.com/medic...
#Hematology #HealthScience #Breakthrough #MedicalScience #ManuscriptSubmission #ScientificResearch #Innovation #Displaycia
Bottom line - the LLN for Ferritin in both women and men should be at least 30 in the absence of inflammation and chronic kidney disease.
Non-anemic iron deficiency (NAID) and iron deficiency anemia (IDA) affect millions of women, yet many are often underdiagnosed and undertreated.
Why? Structural barriers, inconsistent diagnostic thresholds, and lack of awareness.
Learn more: https://bit.ly/4c901LU
#Hematology #HemeSky
Why? Structural barriers, inconsistent diagnostic thresholds, and lack of awareness.
Learn more: https://bit.ly/4c901LU
#Hematology #HemeSky
April 7, 2025 at 12:33 PM
Bottom line - the LLN for Ferritin in both women and men should be at least 30 in the absence of inflammation and chronic kidney disease.
Reposted
FARES-II: Much anticipated randomized trial @jama.com comparing Plasma to PCC in cardiac surgery (n=420)
Those in PCC arm had ↑ hemostatic efficacy and ↓ RBC transfusion
Hopefully practice-changing for many!
jamanetwork.com/journals/jam...
#transfusion #hemesky
Those in PCC arm had ↑ hemostatic efficacy and ↓ RBC transfusion
Hopefully practice-changing for many!
jamanetwork.com/journals/jam...
#transfusion #hemesky
March 31, 2025 at 3:40 AM
FARES-II: Much anticipated randomized trial @jama.com comparing Plasma to PCC in cardiac surgery (n=420)
Those in PCC arm had ↑ hemostatic efficacy and ↓ RBC transfusion
Hopefully practice-changing for many!
jamanetwork.com/journals/jam...
#transfusion #hemesky
Those in PCC arm had ↑ hemostatic efficacy and ↓ RBC transfusion
Hopefully practice-changing for many!
jamanetwork.com/journals/jam...
#transfusion #hemesky
Finally! More data to add to the EVE trial
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism | NEJM
In patients with active cancer and venous thromboembolism, whether extended treatment
with a reduced dose of an oral anticoagulant is effective in preventing recurrent
thromboembolic events and dec...
www.nejm.org
March 30, 2025 at 8:13 PM
Finally! More data to add to the EVE trial
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
APICAT showed non inferiority of apixaban 2.5BD in patients with CAVTE who have completed 6m anticoagulation to 5BD in terms of VTE recurrence (2.1% v 2.8%) and lower clinically relevant bleeding (12.1% v 15.6%)
#Hemesky #BSH
www.nejm.org/doi/full/10....
Reposted
New in The Journal of Haemophilia Practice: a paper reporting on the hopes and goals of a group of men with #haemophilia B, including how new treatments, such as #genetherapy, could help support and redefine their aspirations. Open access here: loom.ly/vJmE2Wg
#HemeSky #BloodSky #MedSky
#HemeSky #BloodSky #MedSky
March 24, 2025 at 7:25 AM
New in The Journal of Haemophilia Practice: a paper reporting on the hopes and goals of a group of men with #haemophilia B, including how new treatments, such as #genetherapy, could help support and redefine their aspirations. Open access here: loom.ly/vJmE2Wg
#HemeSky #BloodSky #MedSky
#HemeSky #BloodSky #MedSky
Reposted
RPTH Cares about Women's Health 🌸: NAID and IDA are extremely prevalent among women, largely due to iron losses from vaginal blood loss.
Explore the findings: www.rpthjournal.org/article/S247...
@isth.org
#IronDeficiency #WomensHealth
Explore the findings: www.rpthjournal.org/article/S247...
@isth.org
#IronDeficiency #WomensHealth
The detrimental impact of ferritin “normal” ranges on diagnosis of bleeding disorders in women
In this editorial, we use the term “women” to highlight the experiences of and care
gaps for women with nonanemic iron deficiency (NAID) and iron deficiency anemia (IDA)
and the term “females” in refe...
www.rpthjournal.org
March 17, 2025 at 7:00 PM
RPTH Cares about Women's Health 🌸: NAID and IDA are extremely prevalent among women, largely due to iron losses from vaginal blood loss.
Explore the findings: www.rpthjournal.org/article/S247...
@isth.org
#IronDeficiency #WomensHealth
Explore the findings: www.rpthjournal.org/article/S247...
@isth.org
#IronDeficiency #WomensHealth
Reposted
#ASHWomenWednesday ♀️🩸: Learn about why hematologists should care about heavy periods, and test your knowledge with a quick quiz.
Share your insights in the comments!
#ASHEducation #ASHWomenWednesday #WomenInHeme #Shematology #BloodSisters #HemeHeroines #BloodEducation #Microlearning #Hematology
Share your insights in the comments!
#ASHEducation #ASHWomenWednesday #WomenInHeme #Shematology #BloodSisters #HemeHeroines #BloodEducation #Microlearning #Hematology
March 5, 2025 at 4:48 PM
#ASHWomenWednesday ♀️🩸: Learn about why hematologists should care about heavy periods, and test your knowledge with a quick quiz.
Share your insights in the comments!
#ASHEducation #ASHWomenWednesday #WomenInHeme #Shematology #BloodSisters #HemeHeroines #BloodEducation #Microlearning #Hematology
Share your insights in the comments!
#ASHEducation #ASHWomenWednesday #WomenInHeme #Shematology #BloodSisters #HemeHeroines #BloodEducation #Microlearning #Hematology
Funny things patients say in clinic - part 1
“I don’t like those compression stockings for my post thrombotic syndrome. They’re tight” 🧐🧐🧐
#Hemesky
“I don’t like those compression stockings for my post thrombotic syndrome. They’re tight” 🧐🧐🧐
#Hemesky
February 14, 2025 at 4:20 PM
Funny things patients say in clinic - part 1
“I don’t like those compression stockings for my post thrombotic syndrome. They’re tight” 🧐🧐🧐
#Hemesky
“I don’t like those compression stockings for my post thrombotic syndrome. They’re tight” 🧐🧐🧐
#Hemesky
I have sympathy for Americans who can no longer access clinical trials due to politicization of healthcare by ignorant folk
At the same time, I hope people can appreciate the lack of access to the most basic healthcare (which people take for granted) in >80% of the world, including many war zones.
At the same time, I hope people can appreciate the lack of access to the most basic healthcare (which people take for granted) in >80% of the world, including many war zones.
January 26, 2025 at 11:40 AM
I have sympathy for Americans who can no longer access clinical trials due to politicization of healthcare by ignorant folk
At the same time, I hope people can appreciate the lack of access to the most basic healthcare (which people take for granted) in >80% of the world, including many war zones.
At the same time, I hope people can appreciate the lack of access to the most basic healthcare (which people take for granted) in >80% of the world, including many war zones.
Simple cheap intervention, low risk of side effects, improved outcomes for mum (lower PPH, lower risk RBC transfusion and allomunisation, feeling better in herself) and now for baby!
This is ripe for low-middle income country quality improvement initiatives. @who.int
This is ripe for low-middle income country quality improvement initiatives. @who.int
A single infusion of IV ferric carboxymaltose in the third trimester of pregnancy significantly lowered the occurrence of anemia before childbirth in a new study, outperforming the efficacy of iron tablets.
🔗 www.hcplive.com/view/iv-iron...
#Hematology #IronDeficiency #WomensHealth
🔗 www.hcplive.com/view/iv-iron...
#Hematology #IronDeficiency #WomensHealth
January 22, 2025 at 6:26 AM
Simple cheap intervention, low risk of side effects, improved outcomes for mum (lower PPH, lower risk RBC transfusion and allomunisation, feeling better in herself) and now for baby!
This is ripe for low-middle income country quality improvement initiatives. @who.int
This is ripe for low-middle income country quality improvement initiatives. @who.int
Reposted
This week in @bloodjournal.bsky.social, data from the STOPAGO trial showed that almost half of patients who achieved remission from chronic ITP while on TPO receptor agonist therapy were able to stop their TPO-RA and remain in remission at four years. #hemesky #ITP
STOP & GO: discontinuing TPO-RA in chronic ITP
In this issue of Blood, Cottu and colleagues present data from the STOPAGO study demonstrating that nearly half of the patients with chronic ITP who achiev
ashpublications.org
January 10, 2025 at 8:46 PM
This week in @bloodjournal.bsky.social, data from the STOPAGO trial showed that almost half of patients who achieved remission from chronic ITP while on TPO receptor agonist therapy were able to stop their TPO-RA and remain in remission at four years. #hemesky #ITP
Since dreaming is free, here is my Haemostasis and Thrombosis Wishlist for 2025 (a 🧵)
1. Upfront Emicizumab for acquired Haemophilia A
2. Point of Care DOAC assays to dictate need for reversal (<50 vs >50)
(1/4)
1. Upfront Emicizumab for acquired Haemophilia A
2. Point of Care DOAC assays to dictate need for reversal (<50 vs >50)
(1/4)
December 28, 2024 at 3:24 PM
Since dreaming is free, here is my Haemostasis and Thrombosis Wishlist for 2025 (a 🧵)
1. Upfront Emicizumab for acquired Haemophilia A
2. Point of Care DOAC assays to dictate need for reversal (<50 vs >50)
(1/4)
1. Upfront Emicizumab for acquired Haemophilia A
2. Point of Care DOAC assays to dictate need for reversal (<50 vs >50)
(1/4)